CD14+CD16+ and CD14+CD163+ monocyte subpopulations in kidney allograft transplantation.

BMC Immunol · 2014 · PMC3918100 · PMID 24499053

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In patients treated with anti-CD25 antibody basiliximab, the decrease in percentage of CD14+CD16+ reached the minimum after two weeks and the moderate changes did not reach statistical significance (p = ns) (Figures 1 and 2 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.